BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement to deprioritize the development of luvelta. Management said the decision was largely based on their current cash position and highlighted ongoing discussions with other companies regarding luvelta out-licensing opportunities, but it is remains unclear the status of these discussions and the expected timing of a partnership announcement, notes the analyst, who removes all value for luvelta from the firm’s model and notes that luvelta was the primary driver of the firm’s prior Buy thesis.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma downgraded to Underperform from Buy at BofA
- Cautious Hold Rating on Sutro Biopharma Amid Strategic Shift and Restructuring
- Sutro Biopharma’s Strategic Shift: Hold Rating Amid Reprioritization and Financial Restructuring
- Sutro Biopharma downgraded to Neutral from Outperform at Wedbush
- Sutro Biopharma downgraded to Market Perform from Outperform at Citizens JMP